July 16, 2025Open Access

Regulatory T Cell Dysregulation in Vitiligo: A Meta‐Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives

GLG. Rozenbaum LernerUniversity of Miami MNMaria Nikolaou CSCorinne I. StoffelUniversity of Zurich

Key Points

A total of 21 studies with 1016 vitiligo patients and 846 healthy controls were analyzed.
Significant reductions in peripheral regulatory t cell counts and their suppressive capacity were found in vitiligo patients (p = 0.01).
Levels of immunoregulatory cytokine interleukin-10 were lower (p = 0.02), while pro-inflammatory cytokines interleukin-17 and interleukin-22 were elevated (p ≤ 0.01).
Reduced expression of the suppressive marker FOXP3 was consistently reported in both skin and blood of vitiligo patients.

Abstract

ABSTRACT Vitiligo is an autoimmune disorder marked by the progressive loss of skin melanocytes, increasingly linked to immune dysregulation as a key driver of disease onset and progression. Regulatory T (Treg) cells are essential for maintaining immune homeostasis by suppressing autoreactive immune responses. Mounting evidence implicates functional and numerical alterations in Treg cells in the pathogenesis of vitiligo. This study reviews findings on lesional and circulating Treg cells in vitiligo patients compared to healthy controls (HCs), examining Treg cell frequency, their ability to suppress CD4 + and CD8 + T cell activity, levels of the immunoregulatory cytokines interleukin‐10 (IL‐10) and transforming growth factor‐β (TGF‐β), expression of the key suppressive marker FOXP3, as well as levels of the pro‐inflammatory cytokines interleukin‐17 (IL‐17) and interleukin‐22 (IL‐22). A comprehensive systematic search was performed across Embase, MEDLINE/PubMed, and Scopus databases to identify eligible studies. A total of 21 studies comprising 1016 vitiligo patients and 846 HCs were included in the review. The analysis revealed a significant reduction in peripheral Treg cell counts ( p = 0.01), impaired overall suppressive capacity of CD4+ and CD8+ T cells ( p = 0.01), reduced levels of IL‐10 ( p = 0.02), increased levels of IL‐17 ( p ≤ 0.01) and IL‐22 ( p ≤ 0.01) in the blood of vitiligo patients compared to HCs. No statistically significant difference was observed in circulating TGF‐β levels ( p = 0.1). Most studies reported reduced FOXP3 expression in both skin and blood of vitiligo patients. Current evidence suggests vitiligo involves both reduced numbers and impaired function of Treg cells, supporting further study of Treg pathways as targets for immunomodulatory therapy.

Ask AI

Helpful

Bookmark

View Full Paper